Leon F. Tseng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Leon F. Tseng has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Hirokazu Mizoguchi
Department of Anesthesiology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
5 shared publicationsHsiang-En Wu
Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
5 shared publicationsHiroshi Nagase
Pharmaceutical Research Laboratory, Toray Industries Inc., Kamakura, Kanagawa 248-8555, Japan
4 shared publicationsMaia Terashvili
Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
3 shared publicationsMinoru Narita
Department of Toxicology, School of Pharmacy, Hoshi University, Shinagawa, Tokyo 142-8501, Japan
3 shared publicationsKuei-Chun Hung
Department of Anesthesiology, Medical College of Wisconsin, Medical Education Building, Room 462c, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
2 shared publications
Latest Publications
- 1 October 2007
- Published by Elsevier in European Journal of Pharmacology
- Vol. 571 (2-3) , 145-151
Stereoselective action of (+)-morphine over (−)-morphine in attenuating the (−)-morphine-produced antinociception via the naloxone-sensitive sigma receptor in the mouse
- 1 October 2007
- Published by Elsevier in European Journal of Pharmacology
- Vol. 571 (2-3) , 145-151
Stereoselective action of (+)-morphine over (−)-morphine in attenuating the (−)-morphine-produced antinociception via the naloxone-sensitive sigma receptor in the mouse
- 13 November 2006
- Published by Wiley in European Journal of Neuroscience
- Vol. 24 (9) , 2575-2580
dextro‐Naloxone orlevo‐naloxone reverses the attenuation of morphine antinociception induced by lipopolysaccharide in the mouse spinal cord via a non‐opioid mechanism
Glial stimulation by intrathecal injection of lipopolysaccharide (LPS) attenuated the tail‐flick inhibition produced by morphine given intrathecally in the spinal cord of the male CD‐1 mice. The phenomenon has been defined as antianalgesia. The effects ofdextro‐naloxone orlevo‐naloxone on the attenuation of morphine‐produced tail‐flick inhibition induced by LPS were then studied. Pretreatment withdextro‐naloxone orlevo‐naloxone reversed the attenuation of the morphine‐produced tail‐flick inhibition induced by LPS. Pretreatment withdextro‐naloxone orlevo‐naloxone alone did not affect the morphine‐produced tail‐flick inhibition. It is concluded thatdextro‐naloxone andlevo‐naloxone block the LPS‐induced antianalgesia against morphine antinociception via a non‐opioid mechanism.
- 13 November 2006
- Published by Wiley in European Journal of Neuroscience
- Vol. 24 (9) , 2575-2580
dextro‐Naloxone orlevo‐naloxone reverses the attenuation of morphine antinociception induced by lipopolysaccharide in the mouse spinal cord via a non‐opioid mechanism
Glial stimulation by intrathecal injection of lipopolysaccharide (LPS) attenuated the tail‐flick inhibition produced by morphine given intrathecally in the spinal cord of the male CD‐1 mice. The phenomenon has been defined as antianalgesia. The effects ofdextro‐naloxone orlevo‐naloxone on the attenuation of morphine‐produced tail‐flick inhibition induced by LPS were then studied. Pretreatment withdextro‐naloxone orlevo‐naloxone reversed the attenuation of the morphine‐produced tail‐flick inhibition induced by LPS. Pretreatment withdextro‐naloxone orlevo‐naloxone alone did not affect the morphine‐produced tail‐flick inhibition. It is concluded thatdextro‐naloxone andlevo‐naloxone block the LPS‐induced antianalgesia against morphine antinociception via a non‐opioid mechanism.
- 17 October 2006
- Published by Elsevier in European Journal of Pharmacology
- Vol. 554 (2-3) , 137-144
Paradoxical hyperalgesia induced by μ-opioid receptor agonist endomorphin-2, but not endomorphin-1, microinjected into the centromedial amygdala of the rat
- 17 October 2006
- Published by Elsevier in European Journal of Pharmacology
- Vol. 554 (2-3) , 137-144
Paradoxical hyperalgesia induced by μ-opioid receptor agonist endomorphin-2, but not endomorphin-1, microinjected into the centromedial amygdala of the rat
- 14 January 2004
- Published by Elsevier in Neuroscience Letters
- Vol. 356 (2) , 145-147
Region-dependent G-protein activation by κ-opioid receptor agonists in the mouse brain
- 14 January 2004
- Published by Elsevier in Neuroscience Letters
- Vol. 356 (2) , 145-147
Region-dependent G-protein activation by κ-opioid receptor agonists in the mouse brain
- Open Access
- 1 July 2003
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 306 (1) , 394-400
Buprenorphine Blocks ϵ- and μ-Opioid Receptor-Mediated Antinociception in the Mouse
Antagonistic properties of buprenorphine for ϵ- and μ-opioid receptors were characterized in β-endorphin- and [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO)-induced antinociception, respectively, with the tail-flick test in male ICR mice. ϵ-Opioid receptor agonist β-endorphin (0.1–1 μg), μ-opioid receptor agonist DAMGO (0.5–20 ng), or buprenorphine (0.1–20 μg) administered i.c.v. dose dependently produced antinociception. The antinociception induced by 10 μg of buprenorphine given i.c.v. was completely blocked by the pretreatment with β-funaltrexamine (β-FNA) (0.3 μg i.c.v.), indicating that the buprenophine-induced antinociception is mediated by the stimulation of the μ-opioid receptor. The antinociceptive effects induced by β-endorphin (1 μg i.c.v.) and DAMGO (16 ng i.c.v.) were dose dependently blocked by pretreatment with smaller doses of buprenorphine (0.001–1 μg i.c.v.), but not by a higher dose of buprenorphine (10 μg i.c.v.). β-FNA at a dose (0.3 μg i.c.v.) that strongly attenuated DAMGO-induced antinociception had no effect on the antinociception produced by β-endorphin (1 μg i.c.v.). However, pretreatment with buprenorphine (0.1–10 μg) in mice pretreated with this same dose of β-FNA was effective in blocking β-endorphin-induced antinociception. β-FNA was 226-fold more effective at antagonizing the antinociception induced by DAMGO (16 ng i.c.v.) than by β-endorphin (1 μg i.c.v.). The antinociception induced by δ-opioid receptor agonist [d-Ala2]deltorphin II (10 μg i.c.v.) or κ1-opioid receptor agonist trans-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl]cyclohexyl)benzeneacetamine methanesulfonate salt [(–)-U50,488H] (75 μg i.c.v.) was not affected by pretreatment with buprenorphine (0.1–1.0 μg i.c.v.). It is concluded that buprenorphine, at small doses, blocks ϵ-opioid receptor-mediated β-endorphin-induced antinociception and μ-opioid receptor-mediated DAMGO-induced antinociception, and at high doses produces a μ-opioid receptor-mediated antinociception.
- 1 July 2003
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 306 (1) , 394-400
Open AccessBuprenorphine Blocks ϵ- and μ-Opioid Receptor-Mediated Antinociception in the Mouse
Antagonistic properties of buprenorphine for ϵ- and μ-opioid receptors were characterized in β-endorphin- and [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO)-induced antinociception, respectively, with the tail-flick test in male ICR mice. ϵ-Opioid receptor agonist β-endorphin (0.1–1 μg), μ-opioid receptor agonist DAMGO (0.5–20 ng), or buprenorphine (0.1–20 μg) administered i.c.v. dose dependently produced antinociception. The antinociception induced by 10 μg of buprenorphine given i.c.v. was completely blocked by the pretreatment with β-funaltrexamine (β-FNA) (0.3 μg i.c.v.), indicating that the buprenophine-induced antinociception is mediated by the stimulation of the μ-opioid receptor. The antinociceptive effects induced by β-endorphin (1 μg i.c.v.) and DAMGO (16 ng i.c.v.) were dose dependently blocked by pretreatment with smaller doses of buprenorphine (0.001–1 μg i.c.v.), but not by a higher dose of buprenorphine (10 μg i.c.v.). β-FNA at a dose (0.3 μg i.c.v.) that strongly attenuated DAMGO-induced antinociception had no effect on the antinociception produced by β-endorphin (1 μg i.c.v.). However, pretreatment with buprenorphine (0.1–10 μg) in mice pretreated with this same dose of β-FNA was effective in blocking β-endorphin-induced antinociception. β-FNA was 226-fold more effective at antagonizing the antinociception induced by DAMGO (16 ng i.c.v.) than by β-endorphin (1 μg i.c.v.). The antinociception induced by δ-opioid receptor agonist [d-Ala2]deltorphin II (10 μg i.c.v.) or κ1-opioid receptor agonist trans-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl]cyclohexyl)benzeneacetamine methanesulfonate salt [(–)-U50,488H] (75 μg i.c.v.) was not affected by pretreatment with buprenorphine (0.1–1.0 μg i.c.v.). It is concluded that buprenorphine, at small doses, blocks ϵ-opioid receptor-mediated β-endorphin-induced antinociception and μ-opioid receptor-mediated DAMGO-induced antinociception, and at high doses produces a μ-opioid receptor-mediated antinociception.
- 7 February 2003
- Published by Elsevier in European Journal of Pharmacology
- Vol. 461 (1) , 35-39
Blockade of μ-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice
- 7 February 2003
- Published by Elsevier in European Journal of Pharmacology
- Vol. 461 (1) , 35-39
Blockade of μ-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice
- 9 November 2002
- Published by Elsevier in Neuroscience
- Vol. 115 (3) , 715-721
Antagonistic property of buprenorphine for putative ϵ-opioid receptor-mediated G-protein activation by β-endorphin in pons/medulla of the μ-opioid receptor knockout mouse
- 9 November 2002
- Published by Elsevier in Neuroscience
- Vol. 115 (3) , 715-721
Antagonistic property of buprenorphine for putative ϵ-opioid receptor-mediated G-protein activation by β-endorphin in pons/medulla of the μ-opioid receptor knockout mouse
- 28 July 2002
- Published by Elsevier in European Journal of Pharmacology
- Vol. 448 (2-3) , 169-174
Acute antinociceptive tolerance and unidirectional cross-tolerance to endomorphin-1 and endomorphin-2 given intraventricularly in the rat
- 28 July 2002
- Published by Elsevier in European Journal of Pharmacology
- Vol. 448 (2-3) , 169-174
Acute antinociceptive tolerance and unidirectional cross-tolerance to endomorphin-1 and endomorphin-2 given intraventricularly in the rat
- Open Access
- 1 January 2002
- Published by Elsevier in The Japanese Journal of Pharmacology
- Vol. 89 (3) , 216-220
Recent Advances in the Search for the μ-Opioidergic System: The Antinociceptive Properties of Endomorphin-1 and Endomorphin-2 in the Mouse
Two highly selective mu-opioid receptor agonists, endomorphin-1 (EM-1) and endomorphin-2 (EM-2), have been identified and postulated to be endogenous mu-opioid receptor ligands. The present minireview describes the antinociceptive properties with the tail-flick test of these two ligands given intracerebroventricularly (i.c.v.) and intrathecally (i.t.) in ICR mice. EM-1 or EM-2 given i.c.v. or i.t. dose-dependently produce antinociception. These antinociceptive effects induced by EM-1 and EM-2 given i.c.v. or i.t. are selectively mediated by the stimulation of mu-, but not delta- or kappa-opioid receptors. Like other mu-opioid agonists morphine and DAMGO ([D-Ala2,NMePhe4,Gly5-ol]enkephalin), EM-1 and EM-2 given i.c.v. activate descending pain controls by the releases of noradrenaline and 5-HT and subsequently act on alpha2-adrenoceptors and 5-HT receptors, respectively, in the spinal cord to produce antinociception. However, the antinociception induced by EM-2 given i.c.v. or i.t. also contain an additional component, which is mediated by the release of dynorphin A(1-17) acting on kappa-opioid receptors at the supraspinal and spinal sites. In addition, the antinociception induced by EM-2 given i.c.v. contains another component, which is mediated by the release of Met-enkephalin acting on delta2-opioid receptors in the spinal cord. It is proposed that there are two subtypes of mu-opioid receptors,which are involved in EM-1- and EM-2-induced antinociception. One subtype of mu-opioid receptors is stimulated by EM-1, EM-2 and other mu-opioid agonists morphine and DAMGO; and another subtype of mu-opioid is sorely stimulated by EM-2 and is involved in the releases of dynorphin A(1-17) and Met-enkephalin for the production of antinociception.
- 1 January 2002
- Published by Elsevier in The Japanese Journal of Pharmacology
- Vol. 89 (3) , 216-220
Open AccessRecent Advances in the Search for the μ-Opioidergic System: The Antinociceptive Properties of Endomorphin-1 and Endomorphin-2 in the Mouse
Two highly selective mu-opioid receptor agonists, endomorphin-1 (EM-1) and endomorphin-2 (EM-2), have been identified and postulated to be endogenous mu-opioid receptor ligands. The present minireview describes the antinociceptive properties with the tail-flick test of these two ligands given intracerebroventricularly (i.c.v.) and intrathecally (i.t.) in ICR mice. EM-1 or EM-2 given i.c.v. or i.t. dose-dependently produce antinociception. These antinociceptive effects induced by EM-1 and EM-2 given i.c.v. or i.t. are selectively mediated by the stimulation of mu-, but not delta- or kappa-opioid receptors. Like other mu-opioid agonists morphine and DAMGO ([D-Ala2,NMePhe4,Gly5-ol]enkephalin), EM-1 and EM-2 given i.c.v. activate descending pain controls by the releases of noradrenaline and 5-HT and subsequently act on alpha2-adrenoceptors and 5-HT receptors, respectively, in the spinal cord to produce antinociception. However, the antinociception induced by EM-2 given i.c.v. or i.t. also contain an additional component, which is mediated by the release of dynorphin A(1-17) acting on kappa-opioid receptors at the supraspinal and spinal sites. In addition, the antinociception induced by EM-2 given i.c.v. contains another component, which is mediated by the release of Met-enkephalin acting on delta2-opioid receptors in the spinal cord. It is proposed that there are two subtypes of mu-opioid receptors,which are involved in EM-1- and EM-2-induced antinociception. One subtype of mu-opioid receptors is stimulated by EM-1, EM-2 and other mu-opioid agonists morphine and DAMGO; and another subtype of mu-opioid is sorely stimulated by EM-2 and is involved in the releases of dynorphin A(1-17) and Met-enkephalin for the production of antinociception.